Lymphoma

Podcasts

For the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® sat down with Gilles Salles, MD, to discuss different treatment regimens for transplant-ineligible DLBCL in this special edition episode.

Oncology Peer Review On-The-Go: Emerging and Existing Treatment Regimens for Transplant-Ineligible DLBCL

Articles

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA. 

Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel

Clinical activity with the combination of naratuximab emtansine plus rituximab was observed in patients with relapsed or refractory diffuse large B-cell lymphoma.


Relapsed/Refractory DLBCL Has Extended Response Duration With Naratuximab Emtansine Plus Rituximab

Updated data from the pivotal L-MIND trial that were presented at the 2021 ASCO Annual Meeting continue to support the use of tafasitamab-cxix in patients with relapsed/refractory diffuse large B-cell lymphoma. 

Responses to Tafasitamab/Lenalidomide in DLBCL Sustained at Three Years 

The novel combination of polatuzumab vetodin, rituximab and lenalidomide improved overall response and complete response for patients with relapsed/refractory diffuse large B-cell lymphoma.

Triplet Combo of Polatuzumab Vedotin, Rituximab and Lenalidomide Safe, Effective to Treat Relapsed/Refractory DLBCL

Phase 2 data supporting the use of loncastuximab tesirine in patients with diffuse large B-cell lymphoma published in The Lancet Oncology show the agent inducing a response in about half of patients with pretreated disease.

Loncastuximab Tesirine Produces Significant Antitumor Response in Relapsed/Refractory DLBCL

Results of a study found that ctDNA could provide an immediate benefit for mitigating selection bias in DLBCL-centered clinical trials.

Circulating Tumor DNA Levels Effective for Measuring Disease Burden in Diffuse Large B-Cell Lymphoma

Data from the phase 2 LOTIS-2 clinical trial supported the accelerated approval of loncastuximab tesirine for patients with relapsed or refractory large B-cell lymphoma. 

FDA Approves Loncastuximab Tesirine in Patients with R/R Large B-Cell Lymphoma

Videos

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCL

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma | Topics